Structure Therapeutics (Nasdaq: GPCR) is a South San Francisco biotech built on structure-based design of orally available small molecules targeting G-protein-coupled receptors. Its lead asset aleniglipron (GSBR-1290) is the cleanest non-Lilly challenger in the oral GLP-1 race and has emerged as the obesity field's strongest oral non-incretin-peptide candidate outside Foundayo.
The Phase 2b ACCESS program is the data engine. ACCESS II delivered up to 16.3% placebo-adjusted weight loss over 44 weeks, the strongest oral GLP-1 number outside Lilly's orforglipron, with a tolerability profile that held under titration. The full dataset was published in Nature Medicine on June 5, 2026, with a same-day ADA Scientific Sessions oral presentation by Julio Rosenstock. Structure has end-of-Phase-2 FDA alignment and starts Phase 3 in Q3 2026 with a 2.5 mg starting dose, alongside amylin and combination programs. The company has been called out by analysts as a likely acquisition target as Lilly and Novo consolidate the obesity field.
Stories here cover aleniglipron readouts, Structure's broader GPCR pipeline, and the company's market positioning. See #aleniglipron, #access, and #oral-glp-1 for adjacent threads.
BioSpace's reaction to AstraZeneca's elecoglipron VISTA Phase 2b readout (10.5% weight loss at 26 weeks) framed it as 'relatively underwhelming' next to Structure Therapeutics' aleniglipron (up to 16.3% at 44 weeks, Nature Medicine publication on Friday). Both are oral small-molecule GLP-1s with Phase 3 plans for the second half of 2026, but elecoglipron's lower number gives Structure a clearer differentiation story heading into its Phase 3 start. AstraZeneca will lean on its combination strategy with dapagliflozin and AZD0780 to position elecoglipron.
Nature Medicine published Structure's Phase 2b ACCESS trial of aleniglipron, the once-daily oral small-molecule GLP-1, on June 5, with lead author Julio Rosenstock presenting the full data in a 12:45 p.m. CT oral session at ADA 2026 the same afternoon. The 44-week ACCESS II readout reached up to 16.3% placebo-adjusted weight loss, the strongest oral GLP-1 number outside Lilly's, and Structure plans to start Phase 3 in Q3 2026 with a 2.5 mg starting dose after end-of-Phase-2 FDA alignment.
Structure Therapeutics will present five obesity and diabetes studies at ADA 2026, anchored by its once-daily oral small-molecule GLP-1 aleniglipron, which posted up to 16.3% placebo-adjusted weight loss at 44 weeks in the Phase 2 ACCESS II trial, among the highest reported for an oral GLP-1. The company has FDA end-of-Phase-2 alignment and plans to start a Phase 3 obesity trial in Q3 2026, with amylin and combination data also on the slate.